Chace DH, Pons R, Chiriboga CA, McMahon DJ, Tein I, Naylor EW, et al
This is sometimes called multi-modal therapy
Following the successful completion of clinical trials, it was approved in 1997 for the diagnosis and treatment of growth hormone deficiency in children
These benefits were further supported by the results of the SUMMIT trial, which investigated tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, in patients with HFpEF with or without T2D
The most useful way to understand Retatrutide is not as a quick solution, but as part of a wider shift toward more advanced metabolic research